New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors

Current Opinion in Oncology

Volumn 21, Issue 4, 2009, Pages 327-331

  Park, Min S ^a   Araujo, Dejka M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antiangiogenesis; Hemangiopericytoma; Solitary fibrous tumor; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SOLITARY FIBROUS TUMOR; SPECTRUM; THROMBOCYTOPENIA; PATHOLOGY;

HEMANGIOPERICYTOMA; HUMANS; SOLITARY FIBROUS TUMORS;

EID: 67650309545     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832c9532     Document Type: Review

References (53)

1. Stout AP, Murray MR. Hemangiopericytoma: a vascular tumor featuring Zimmermann's pericytes. Ann Surg 1942; 116:20-33.
2. Gengler C, Guillou L. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 2006; 28:67-74.
3. Stout AP. Hemangiopricytoma: a study of twenty-five new cases. Cancer 1949; 2:1027-1034.
4. Enzinger FM, Smith BH. Hemangiopericytoma. An analysis of 106 cases. Hum Pathol 1976; 7:61 -82.
5. Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG. Meningeal hemangio- pericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 1989; 25:514-522.
6. Spitz FR, Bouvet M, Pisters PWT, et al. Hemangiopericytoma: a 20-year single-institution experience. Ann Surg Oncol 1998; 5:350-355.
7. Mena H, Ribas JL, Pezeshkpour GH, et al. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 1991; 22:84-91.
8. Shiba H, Misawa T, Kobayashi S, et al. Hemangiopericytoma of the greater omentum. J Gastrointest Surg 2007; 11:549-551.
9. Nergaard M, Hansborg N, Fischer-Rasmussen W. Malignant hemangioper- icytoma of the ovary. Acta Obstet Gynecol Scand 1985; 64:87-89.
10. Koch M, Nielsen GP, Yoon SS. Malignant tumors of blood vessels: angio- sarcomas, hemangioendotheliomas, and hemangiopericytomas. J Surg Oncol 2008; 97:321 -329.
11. Wagner E. Das tuberkelahnliche lymphadenom (der cytogene oder reticulirte tuberkel). Arch Heilk (Leipig) 1870; 11:497.
12. Klemperer P, Rabin CB. Primary neoplasms of the pleura. A report of five cases. Arch Pathol 1931; 11:385-412.
13. Stout AP, Murray MR. Localized pleural mesothelioma: investigation of its characteristics and histogenesis by the method of tissue culture. Arch Pathol 1942; 34:951-964.
14. Ali SZ, Hoon V, Hoda S, et al. Solitary fibrous tumor. A cytologic-histologic study with clinical, radiologic and immunohistochemical correlations. Cancer 1997; 81:116-121.
15. Ide F, Obara K, Mishima K, et al. Ultrastructural spectrum of solitary fibrous tumor: a unique perivascular tumor with alternative lines of differentiation. Virchows Arch 2005; 446:646-652.
16. Brunnemann RB, Ro JY, Ordonez NG, et al. Extrapleural solitary fibrous tumor: a clinicopathologic study of 24 cases. Mod Pathol 1999; 12:1034-1042.
17. Hasegawa T, Matsuno Y, Shimoda T, et al. Extrathoracic solitary fibrous tumours: their histological variability and potentially aggressive behavior. Hum Pathol 1999; 30:1464-1473.
18. Chan JKC. Solitary fibrous tumour: everywhere, and a diagnosis in vogue. Histopathology 1997; 31:568-576.
19. Robinson LA. Solitary fibrous tumor of the pleura. Cancer Control 2006; 13:264-269.
20. Zafar H, Takimoto CH, Weiss G. Doege-Potter syndrome. Med Oncol 2004; 20:403-407.
21. Strom EH, Skjerten F, Aarseth LB, et al. Solitary fibrous tumor of the pluera: an immunohistochemical, electron microscopic and tissue culture study of a tumor producing insulin-like growth factor I in a patient with hypoglycemia. Path Res Pract 1991; 187:109 -113.
22. Fletcher CDM. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006; 48:3-12.
23. Horton ES, Dobin SM, Donner LR. A clonal t(8;12)(p11. 2;q24. 3) as the sole abnormality in a solitary fibrous tumor of the pleura. Cancer Genet Cytogenet 2007; 172:77-79.
24. de Leval L, Defraigne J, Hermans G, et al. Malignant solitary fibrous tumor of the pleura: report of a case with cytogenetic analysis. Virchows Arch 2003; 442:388-392.
25. Miettinen MM, El-Rifai W, Sarlomo-Rikala M, et al. Tumor size-related DNA copy number changes occur in solitary fibrous tumors but not in hemangio- pericytomas. Mod Pathol 1997; 10:1194-1200.
26. Krismann M, Adams H, Jaworska M, et al. Patterns of chromosomal imbalances in benign solitary fibrous tmours of the pleura. Virchows Arch 2000; 437:248 -255.
27. Dal Cin P, Pauwels P, Van den Berghe H. Solitary fibrous tumour of the pleura with t(4:15)(a13;q26). Histopathology 1999; 35:94-95.
28. Debiec-Rychter M, de Wever I, Hegemeijer A, et al. Is 4q13 a recurring breakpoint in solitary fibrous tumors? Cancer Genet Cytogenet 2001; 131:69 -73.
29. Havlik MD, Farnath DA, Bocklage T. Solitary fibrous tumor of the orbit with a t(9;22)(q31;p13). Arch Pathol Lab Med 2000; 124:756-758.
30. Torabi A, Lele SM, DiMaio D, et al. Lack of a common or characteristic cytogenetic anomaly in solitary fibrous tumor. Cancer Genet Cytogenet 2008; 181:60-64.
31. Galanis E, Buckner JC, Scheithauer BW, et al. Management of recurrent meningeal hemangiopericytoma. Cancer 1998; 82:1915-1920.
32. EspatNJ, Lewis JJ, Leung D, et al. Conventional hemangiopericytoma. Modern analysis of outcome. Cancer 2002; 95:1746 -1751.
33. Magdeleinat P, Alifano M, Petino A, et al. Solitary fibrous tumors of the pleura: clinical characteristics, surgical treatment and outcome. Eur J Cardiothorac Surg 2002; 21:1087 -1093.
34. Souyer S, Chang EL, Selek U, et al. Intracranial meningeal hemangiopericy- toma: the role ofradiotherapy. Report of29 cases and review ofthe literature. Cancer 2004; 100:1491 -1497.
35. McMaster MJ, Soule EH, Ivins JC. Hemangiopericytoma. A clinicopathologic study and long-term followup of 60 patients. Cancer 1975; 36:2232-2244.
36. Karpeh MS, Caldwell C, Gaynor JJ, et al. Vascular soft-tissue sarcomas: an analysis of tumor-related mortality. Arch Surg 1991; 126:1474-1481.
37. Munoz AK, BerekJS, Fu YS, et al. Pelvic hemangiopericytomas: a report of five cases and literature review. Gynecol Oncol 1990; 36:380-382.
38. Beadle GF, Hillcoat BL. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol 1983; 22:167 -170.
39. Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery 2008; 63:720-727.
40. Park MS, Lazar AJ, Trent JC, et al.combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/solitary fibrous tumor: an updated analysis [abstract #35064]. In: 14th Connective Tissue Oncologic Society Annual Meeting; 13-15 November 2008; London.
41. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J 2000; 6:S134- S141.
42. Kirn DH, Kramer A. Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst 1996; 88:764-765.
43. Lackner H, Urban C, Dornbusch HJ, et al. Interferon alfa-2a in recurrent metastatic hemangiopericytoma. Med Pediatric Oncol 2003; 40:192-194.
44. Park MS, Patel SR, Ludwig JA, et al.combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor [abstract]. J Clin Oncol 2008; 26:10512.
45. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal ofnew computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759.
46. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST,at least in GIST. J Clin Oncol 2007; 25:1760-1764.
47. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozo- lomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98:2693-2699.
48. Kurzen H, Schmitt S, Naher H, Mohler T. Inhibition of angiogenesis by nontoxic doses of temozolomide. Anticancer Drugs 2003; 14:515-522.
49. Kim JT, Kim JS, Ko KW, et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 2006; 16:33-39.
50. Mathieu V, Neve ND, Le Mercier M, et al.combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human gioblastoma orthotopic xenograft model. Neoplasia 2008; 10:1383-1392.
51. Ryan CW, von Mehren M, Rankin CJ, et al. Phase II intergroup study of sorafenib in advanced soft tissue sarcomas: SWOG 0505 [abstract]. J Clin Oncol 2008; 26:10532.
52. Mulamalla K, Truskinovsky AM, Dudek AZ. Rare case of hemangiopericytoma responds to sunitinib. Transl Res 2008; 151:129-133.
53. Dietzmann K, von Bossanyi P, Warich-Kirches M, et al. Immunohistochem- ical detection of vascular growth factors in angiomatous and atypical meningiomas, as well as hemangiopericytomas. Pathol Res Pract 1997; 193:503-510.